Eli Lilly reports its new cancer drug enzastaurin was able to shrink brain tumors in up to 25% of patients in a trial and stopped tumor growth in another 10%. The drug, which Lilly hopes to get to the market by 2008, cuts off drug supply to tumors and disrupts cell pathway signaling that is vital to tumor cells' survival.

Related Summaries